Phase II clinical trial of third-line Panitumumab and irinotecan or Panitumumab therapy for patients with KRAS wild-type unresectable/recurrent colorectal cancer
Ontology highlight
ABSTRACT: Interventions: Chemotherapy (Panitumumab + irinotecan or panitumumab)
Primary outcome(s): Response rate of Panitumumab + irinotecan regimen
Study Design: Single arm Non-randomized
DISEASE(S): Colorectal Cancer
PROVIDER: 2620093 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA